Stem cell therapy in Japan is offered under the Act on the Safety of Regenerative Medicine. Before a clinic may treat patients with a cell-based therapy, it must write a provision plan for that specific treatment, have it reviewed by a certified committee, and file it with the Ministry of Health, Labour and Welfare (MHLW). This page explains how that system works, what it means for a US patient, and the steps for planning a trip.

What the Japanese system actually controls

Japan's system is a filing and review system for each treatment, not a single approval for "stem cell therapy." Under the Act, a hospital or clinic that wants to provide regenerative medicine must submit a provision plan covering the treatment, its content, the facilities, and the source and processing of the cells (Article 4). Each plan is reviewed, and the MHLW can order changes within a set period (Article 8).

The Act took effect in November 2014. The MHLW says a 2025 amendment added in vivo gene therapy, meaning genes delivered directly into the body without cell processing, to the law. The MHLW also opened an information and reporting window on 2 September 2026 for suspected legal violations or safety concerns.

The Act does not cover approved drugs used as approved, or clinical trials run for product approval (Article 2). Those fall under Japan's pharmaceutical law instead. The two iPS cell-derived products that received conditional, time-limited approval on 6 March 2026 are in that second system. They are described in Japan Approves the First iPS Cell–Derived Products.

The three risk classes

The Act sorts treatments into three classes, defined in Articles 2 and 3 of the Enforcement Regulations:

Interior of a light blue and white medical center lobby with a tiered cylindrical desk, wall sign, shelving, and printer

Class What the regulation covers Examples
Class I (highest risk) ES or iPS cells; genetically modified cells; animal cells; cells processed from someone other than the patient; in vivo nucleic acid delivery Donor-derived umbilical cord cells
Class II Cultured stem cells; cultured cells used to rebuild structure or function; cells used in a non-homologous way The patient's own cultured fat-derived stem cells
Class III Everything else under the Act Many immune cell treatments

The class is set by the treatment as filed, not by how a clinic markets it. A treatment built on donor cells is Class I even if the marketing describes it as "gentle." Class I plans also carry a waiting period: under Article 9, a clinic may not provide a Class I treatment until the MHLW review period has run, which is 90 days from submission unless the MHLW shortens or extends it under Article 8. Changes to a Class I plan, other than minor changes, follow the same review and waiting rules under Article 10.

What a clinic must do after treatment starts

The Act also sets ongoing duties. Clinics must report suspected adverse events (Article 17), and the Enforcement Regulations set reporting deadlines for death, serious harm and other events. Periodic reports to the MHLW are also required. If the certified committee named in the plan gives an opinion on a reported event, the clinic must respect that opinion and take the necessary measures. For a patient, the practical point is simple: a compliant clinic should be able to show you its filed plan for your treatment and explain how it reports problems afterward.

How this compares with the US

The US system is built differently. The FDA regulates most cell products under 21 CFR Part 1271. A product that is minimally manipulated and intended for homologous use only, and that meets the other criteria in 21 CFR 1271.10, can be regulated under Section 361 of the Public Health Service Act. Products that do not qualify need a biologics license or an investigational new drug application. The FDA's consumer page states that the only stem cell products it has approved are blood-forming cells from umbilical cord blood, and it warns of reports of blindness, tumor formation and infections linked to unapproved products.

Illuminated city street at night with cars, crosswalk, and tall commercial buildings including a Mitsukoshi storefront and large signs

The practical difference for a patient is that Japan's regime is a filed plan for a treatment at a named clinic, while the US regime is product-level approval. Neither one shows that a treatment works for a given patient. See Does Stem Cell Therapy Work? for what the evidence shows.

Planning a trip, step by step

  1. Define the condition and the treatment type. Know which cells and which route are involved. A treatment using donor cells is a different regulatory case from one using your own cultured cells.
  2. Gather your records. Clinicians will need diagnoses, discharge summaries, imaging, lab results and current medicines. Ask the clinic which language they accept.
  3. Confirm the provision plan first. Send the clinic's name and the treatment name to our advisors, and we will check whether it has filed a provision plan for that treatment. Do this before you book flights.
  4. Plan the visa with a registered guarantor. Patients from abroad generally need a medical stay visa. The Ministry of Foreign Affairs requires a medical institution's appointment certificate and a guarantor's letter, issued through a registered guarantor. The MOFA guidance was updated on 1 August 2026.
  5. Get written consent. Before treatment, the doctor must explain the treatment in writing and obtain your written consent. The consent explanation must cover costs, compensation for health harm, other treatment options, and the complaint process.
  6. Plan follow-up at home. Ask who you contact after returning, how results will be sent back, and what the clinic will do if a complication appears.

Interior room with a padded table, desk, and orange-brown chair

For a structured pre-screening, you can start with our pre-screening page. For the full sequence of steps, see how getting treated in Japan works, and for the regulatory overview see how Japan regulates regenerative medicine.

Frequently asked questions

Is stem cell therapy legal in Japan?

Yes, when the clinic has filed a provision plan for that specific treatment and follows it. Treatments provided without a filed plan are not permitted under the Act, and the Act sets penalties for that.

Does Japan approve stem cell therapies the way the FDA does?

Not in the same way. Japan's Act is a plan filing and review system for each treatment. Only a small number of cell-derived products have full or conditional marketing approval under pharmaceutical law.

Is stem cell treatment in Japan covered by insurance?

Most clinic-offered regenerative treatments are self-pay. The clinic sets the price, and the patient pays in full. Conditionally approved products are a separate category.

Medical disclaimer: This site provides general information only and does not constitute medical advice; whether any treatment is suitable for you must be decided by a doctor after an in-person consultation.


Sources: Act on the Safety of Regenerative Medicine (Act No. 85 of 2013), e-Gov Law API, Articles 2, 4, 8, 9 and 17; Enforcement Regulations (MHLW Ordinance No. 110 of 2014), e-Gov Law API, Articles 2 and 3 and the reporting provisions; MHLW, Regenerative and Cell Medicine and Gene Therapy page; Japan Science and Technology Agency (JST) Science Portal, 18 March 2026; Ministry of Foreign Affairs, Medical Stay Visa applicant guidance (updated 1 August 2026); US Code of Federal Regulations, 21 CFR 1271.10 (Cornell LII copy); FDA consumer page on regenerative medicine therapies. Checked November 2026; MHLW (or the relevant body) publications prevail.

Medical disclaimer: This site provides general information only and does not constitute medical advice; whether any treatment is suitable for you must be decided by a doctor after an in-person consultation.